Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 16/20 | 0.58 |
| ▸ | PDE4A | P27815 | 11/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927437 | 0.82 | PDE4D (0.45) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL17732270 | 0.75 | PDE4D (0.47) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL12137140 | 0.74 | PDE4A (0.59) | PDE4DPDE4APDE4BPDE4CHSD17B10 | |
| SCHEMBL25871726 | 0.74 | ALDH1A1 (0.48) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL15965424 | 0.74 | CTNNB1 (0.53) | PDE4BTSHR | |
| SCHEMBL15965403 | 0.74 | MEN1 (0.60) | PDE4BTSHR | |
| SCHEMBL30848626 | 0.72 | PTPN1 (0.51) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL12937549 | 0.72 | CTNNB1 (0.51) | PDE4BTSHR | |
| SCHEMBL15965411 | 0.72 | GSK3B (0.56) | PDE4BTSHR | |
| SCHEMBL11335265 | 0.72 | MAPT (0.55) | PDE4BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-10-07 | — | — | US | disclosed |
| EP-3901147-B1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-3901147-B1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| CN-113166116-B | Amido bridged heterocyclic compound, and composition and application thereof | 北京赛特明强医药科技有限公司 | 2022-12-27 | — | — | CN | disclosed |
| EP-3901147-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901147-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-10-27 | — | — | EP | disclosed |
| CN-113166116-A | Amido bridged heterocyclic compound, and composition and application thereof | 北京赛特明强医药科技有限公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | RIPK1, RIPK3, RIPK4 | PDE4D 4119/4885PDE4A 3785/4885PDE4B 4163/4885 |
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | RIPK1, RIPK3, RIPK4 | PDE4D 4119/4885PDE4A 3785/4885PDE4B 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.